

Electronic Acknowledgement Receipt

EFS ID:	4066665
Application Number:	09851743
International Application Number:	
Confirmation Number:	4067
Title of Invention:	Methods for testing compounds useful in treating diabetic complications
First Named Inventor/Applicant Name:	James Nolan
Correspondence Address:	Kevin E. Noonan McDonnell Boehnen Hulbert & Berghoff 32nd Floor 300 S. Wacker Drive Chicago IL 60606 US 3129130001 -
Filer:	Isadora Feliz Bielsky
Filer Authorized By:	
Attorney Docket Number:	00-388-A
Receipt Date:	06-OCT-2008
Filing Date:	09-MAY-2001
Time Stamp:	17:02:14
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 960

RAM confirmation Number	2412				
Deposit Account	132490				
Authorized User					
<p>The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:</p> <p>Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)</p> <p>Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)</p> <p>Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)</p> <p>Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)</p> <p>Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)</p>					
File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Request for Continued Examination (RCE)	00-388-A_RCE.pdf	<div>784057</div> <div>46e819a4570085299f2724104bffc117ced14f95</div>	no	3
Warnings:					
Information:					
2	Extension of Time	00-388-A_extension_time.pdf	<div>334129</div> <div>8bf89016058bdeefdb676ff015b47896c3c5349</div>	no	2
Warnings:					
Information:					
3		00-388-A_OAR_3_19_08.pdf	<div>153265</div> <div>97e7cff3107d9e90c3a944e415611c18bdfcd5b5</div>	yes	18
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Amendment After Final		1	1	
	Claims		2	7	
	Applicant Arguments/Remarks Made in an Amendment		8	18	
Warnings:					
Information:					
4	Fee Worksheet (PTO-06)	fee-info.pdf	<div>31999</div> <div>1616c8cbb098e95eb9acf0970f9a53901b3cd1e9e</div>	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			1303450		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.